Design and Development of COX-II Inhibitors: Current Scenario and Future Perspective

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2023 May 30

PMID 37251190

Authors

Sandhya Chahal

Payal Rani

Kiran

Jayant Sindhu

Gaurav Joshi

Aravindhan Ganesan

Subha Kalyaanamoorthy

Mayank

Parvin Kumar

Rajvir Singh

Arvind Negi

Affiliations

Soon will be listed here.

Abstract

Innate inflammation beyond a threshold is a significant problem involved in cardiovascular diseases, cancer, and many other chronic conditions. Cyclooxygenase (COX) enzymes are key inflammatory markers as they catalyze prostaglandins production and are crucial for inflammation processes. While COX-I is constitutively expressed and is generally involved in "housekeeping" roles, the expression of the COX-II isoform is induced by the stimulation of different inflammatory cytokines and also promotes the further generation of pro-inflammatory cytokines and chemokines, which affect the prognosis of various diseases. Hence, COX-II is considered an important therapeutic target for drug development against inflammation-related illnesses. Several selective COX-II inhibitors with safe gastric safety profiles features that do not cause gastrointestinal complications associated with classic anti-inflammatory drugs have been developed. Nevertheless, there is mounting evidence of cardiovascular side effects from COX-II inhibitors that resulted in the withdrawal of market-approved anti-COX-II drugs. This necessitates the development of COX-II inhibitors that not only exhibit inhibit potency but also are free of side effects. Probing the scaffold diversity of known inhibitors is vital to achieving this goal. A systematic review and discussion on the scaffold diversity of COX inhibitors are still limited. To address this gap, herein we present an overview of chemical structures and inhibitory activity of different scaffolds of known COX-II inhibitors. The insights from this article could be helpful in seeding the development of next-generation COX-II inhibitors.

Citing Articles

Synthesis, and bio-evaluation studies of new isothiocyanate derivatives with respect to COX inhibition and HS release profiles.

Yilmaz Y, Gungor T, Donmez S, Atalay H, Siyah P, Durdagi S RSC Med Chem. 2024; .

PMID: 39507615 PMC: 11536671. DOI: 10.1039/d4md00495g.

Design, Synthesis, and Evaluation of New Imidazo[1,2-]pyridine Derivatives as Cyclooxygenase-2 Inhibitors.

Ahmadi N, Khoramjouy M, Azami Movahed M, Amidi S, Faizi M, Zarghi A Anticancer Agents Med Chem. 2024; 24(7):504-513.

PMID: 38275051 DOI: 10.2174/0118715206269563231220104846.

Lipofuscin, Its Origin, Properties, and Contribution to Retinal Fluorescence as a Potential Biomarker of Oxidative Damage to the Retina.

Rozanowska M Antioxidants (Basel). 2023; 12(12).

PMID: 38136230 PMC: 10740933. DOI: 10.3390/antiox12122111.

Imidazoles as Serotonin Receptor Modulators for Treatment of Depression: Structural Insights and Structure-Activity Relationship Studies.

Goel K, Thapliyal S, Kharb R, Joshi G, Negi A, Kumar B Pharmaceutics. 2023; 15(9).

PMID: 37765177 PMC: 10535231. DOI: 10.3390/pharmaceutics15092208.

References

Smith W, Dewitt D . Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol. 1996; 62:167-215. DOI: 10.1016/s0065-2776(08)60430-7. View

Tietz O, Kaur J, Bhardwaj A, Wuest F . Pyrimidine-based fluorescent COX-2 inhibitors: synthesis and biological evaluation. Org Biomol Chem. 2016; 14(30):7250-7. DOI: 10.1039/c6ob00493h. View

El-Nagar M, Abdu-Allah H, Salem O, Kafafy A, Farghaly H . Novel N-substituted 5-aminosalicylamides as dual inhibitors of cyclooxygenase and 5-lipoxygenase enzymes: Synthesis, biological evaluation and docking study. Bioorg Chem. 2018; 78:80-93. DOI: 10.1016/j.bioorg.2018.02.023. View

Daina A, Michielin O, Zoete V . iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inf Model. 2014; 54(12):3284-301. DOI: 10.1021/ci500467k. View

Kang S, Shin J, Kim S, Noh Y, Lee S, Hwang H . Caffeoyloxy-5,6-dihydro-4-methyl-(2H)-pyran-2-one isolated from the leaves of Olinia usambarensis attenuates LPS-induced inflammatory mediators by inactivating AP-1 and NF-κB. Chem Biol Interact. 2019; 309:108718. DOI: 10.1016/j.cbi.2019.06.031. View

Palkar M, Singhai A, Ronad P, Vishwanathswamy A, Boreddy T, Veerapur V . Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents. Bioorg Med Chem. 2014; 22(10):2855-66. DOI: 10.1016/j.bmc.2014.03.043. View

Tageldin G, Fahmy S, Ashour H, Khalil M, Nassra R, Labouta I . Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidine derivatives bearing thiazolidinone moiety as anti-inflammatory agents. Bioorg Chem. 2018; 80:164-173. DOI: 10.1016/j.bioorg.2018.06.013. View

Kadirvel M, Abudalal A, Rajendran R, Gbaj A, Demonacos C, Freeman S . myo-Inositol esters of indomethacin as COX-2 inhibitors. Carbohydr Res. 2012; 355:13-8. DOI: 10.1016/j.carres.2012.04.008. View

Melagraki G, Afantitis A, Igglessi-Markopoulou O, Detsi A, Koufaki M, Kontogiorgis C . Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts. Eur J Med Chem. 2009; 44(7):3020-6. DOI: 10.1016/j.ejmech.2008.12.027. View

10.

Seth K, Garg S, Kumar R, Purohit P, Meena V, Goyal R . 2-(2-Arylphenyl)benzoxazole As a Novel Anti-Inflammatory Scaffold: Synthesis and Biological Evaluation. ACS Med Chem Lett. 2014; 5(5):512-6. PMC: 4027739. DOI: 10.1021/ml400500e. View

11.

Vane J, Bakhle Y, Botting R . Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38:97-120. DOI: 10.1146/annurev.pharmtox.38.1.97. View

12.

Moneer A, Mohammed K, El-Nassan H . Synthesis of Novel Substituted Thiourea and Benzimidazole Derivatives Containing a Pyrazolone Ring as Anti-Inflammatory Agents. Chem Biol Drug Des. 2015; 87(5):784-93. DOI: 10.1111/cbdd.12712. View

13.

Grover J, Kumar V, Singh V, Bairwa K, Sobhia M, Jachak S . Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors. Eur J Med Chem. 2014; 80:47-56. DOI: 10.1016/j.ejmech.2014.04.033. View

14.

Ren S, Wang Z, Zhu D, Zhu X, Shen F, Wu S . Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy. Eur J Med Chem. 2018; 157:909-924. DOI: 10.1016/j.ejmech.2018.08.048. View

15.

Laube M, Gassner C, Sharma S, Gunther R, Pigorsch A, Konig J . Diaryl-Substituted (Dihydro)pyrrolo[3,2,1-hi]indoles, a Class of Potent COX-2 Inhibitors with Tricyclic Core Structure. J Org Chem. 2015; 80(11):5611-24. DOI: 10.1021/acs.joc.5b00537. View

16.

Dawood K, Eldebss T, El-Zahabi H, Yousef M, Metz P . Synthesis of some new pyrazole-based 1,3-thiazoles and 1,3,4-thiadiazoles as anticancer agents. Eur J Med Chem. 2013; 70:740-9. DOI: 10.1016/j.ejmech.2013.10.042. View

17.

Benet L, Hosey C, Ursu O, Oprea T . BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev. 2016; 101:89-98. PMC: 4910824. DOI: 10.1016/j.addr.2016.05.007. View

18.

Baecker D, Obermoser V, Kirchner E, Hupfauf A, Kircher B, Gust R . Fluorination as tool to improve bioanalytical sensitivity and COX-2-selective antitumor activity of cobalt alkyne complexes. Dalton Trans. 2019; 48(42):15856-15868. DOI: 10.1039/c9dt03330k. View

19.

Gautam R, Srivastava A, Jachak S, Saklani A . Anti-inflammatory, cyclooxygenase (COX)-2, COX-1 inhibitory and antioxidant effects of Dysophylla stellata Benth. Fitoterapia. 2009; 81(1):45-9. DOI: 10.1016/j.fitote.2009.07.004. View

20.

Kim K, Choi M, Shin J, Kim M, Choi H, Kang S . Synthesis, biological evaluation, and docking analysis of a novel family of 1-methyl-1H-pyrrole-2,5-diones as highly potent and selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem Lett. 2014; 24(8):1958-62. DOI: 10.1016/j.bmcl.2014.02.074. View